Latest Insider Transactions at Hca Healthcare, Inc. (HCA)
This section provides a real-time view of insider transactions for Hca Healthcare, Inc. (HCA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HCA Healthcare, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HCA Healthcare, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2024
|
Erol R Akdamar Group President |
SELL
Open market or private sale
|
Direct |
2,900
-29.77%
|
$1,023,700
$353.0 P/Share
|
|
Nov 14
2024
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Open market or private sale
|
Direct |
3,897
-6.89%
|
$1,363,950
$350.0 P/Share
|
|
Nov 12
2024
|
Erol R Akdamar Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
10,257
-51.29%
|
$3,589,950
$350.53 P/Share
|
|
Nov 12
2024
|
Erol R Akdamar Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$1,360,000
$68.96 P/Share
|
|
Nov 12
2024
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Payment of exercise price or tax liability
|
Direct |
4,103
-6.76%
|
$1,436,050
$350.53 P/Share
|
|
Nov 12
2024
|
Phillip G Billington SVP-Internal Audit Services |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+11.64%
|
$544,000
$68.96 P/Share
|
|
Nov 11
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,236
-22.85%
|
$1,155,252
$357.99 P/Share
|
|
Nov 11
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,710
+24.96%
|
$814,830
$173.12 P/Share
|
|
Oct 30
2024
|
Patricia F Elcan > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,021,199
+14.38%
|
$368,652,839
$361.55 P/Share
|
|
Oct 30
2024
|
Patricia F Elcan > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,021,199
-51.82%
|
$368,652,839
$361.55 P/Share
|
|
Sep 12
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
8,358
-21.97%
|
$3,217,830
$385.42 P/Share
|
|
Sep 10
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,722
-26.51%
|
$5,296,692
$386.43 P/Share
|
|
Sep 10
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,080
+29.9%
|
$3,201,600
$145.24 P/Share
|
|
Aug 08
2024
|
Mike A Marks EVP and CFO |
BUY
Bona fide gift
|
Indirect |
2,237
+4.92%
|
-
|
|
Aug 08
2024
|
Mike A Marks EVP and CFO |
SELL
Bona fide gift
|
Direct |
2,237
-100.0%
|
-
|
|
Aug 08
2024
|
Samuel N Hazen CEO |
BUY
Bona fide gift
|
Indirect |
7,115
+32.2%
|
-
|
|
Aug 08
2024
|
Samuel N Hazen CEO |
SELL
Bona fide gift
|
Indirect |
7,115
-100.0%
|
-
|
|
Aug 06
2024
|
Samuel N Hazen CEO |
BUY
Bona fide gift
|
Indirect |
22,211
+47.31%
|
-
|
|
Aug 06
2024
|
Samuel N Hazen CEO |
SELL
Bona fide gift
|
Direct |
22,211
-9.44%
|
-
|
|
Aug 05
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Bona fide gift
|
Indirect |
13,367
+41.91%
|
-
|
|
Aug 05
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Bona fide gift
|
Direct |
13,367
-100.0%
|
-
|
|
Jul 31
2024
|
Timothy M Mc Manus Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,919
-12.67%
|
$1,422,597
$363.05 P/Share
|
|
Jul 31
2024
|
Timothy M Mc Manus Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+19.52%
|
$577,500
$77.13 P/Share
|
|
Jul 31
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
2,987
-24.01%
|
$1,084,281
$363.51 P/Share
|
|
Jul 29
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
1,864
-13.03%
|
$669,176
$359.92 P/Share
|
|
Jul 29
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,293
-27.01%
|
$1,894,894
$358.73 P/Share
|
|
Jul 29
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,280
+29.7%
|
$1,200,600
$145.24 P/Share
|
|
Jul 29
2024
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Open market or private sale
|
Direct |
3,314
-48.56%
|
$1,189,726
$359.96 P/Share
|
|
Jul 29
2024
|
Christopher F. Wyatt SVP & Controller |
SELL
Open market or private sale
|
Direct |
4,000
-9.0%
|
$1,440,000
$360.2 P/Share
|
|
Jul 25
2024
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
5,278
-10.61%
|
$1,857,856
$352.79 P/Share
|
|
Jul 25
2024
|
Christopher F. Wyatt SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
9,300
+15.76%
|
$939,300
$101.16 P/Share
|
|
Jul 25
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
1,857
-9.47%
|
$659,235
$355.05 P/Share
|
|
May 17
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,861
-20.18%
|
$921,242
$322.86 P/Share
|
|
May 17
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,725
+15.1%
|
$552,825
$117.35 P/Share
|
|
May 16
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
3,204
-25.31%
|
$1,044,504
$326.3 P/Share
|
|
May 15
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
1,863
-8.68%
|
$607,338
$326.18 P/Share
|
|
May 15
2024
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,258
-34.68%
|
$6,930,108
$326.96 P/Share
|
|
May 15
2024
|
Jon M Foster EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,465
+28.56%
|
$2,959,875
$75.77 P/Share
|
|
May 15
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,908
-42.57%
|
$3,230,008
$326.96 P/Share
|
|
May 15
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+44.94%
|
$1,292,000
$68.96 P/Share
|
|
May 09
2024
|
Erol R Akdamar Group President |
BUY
Bona fide gift
|
Indirect |
5,139
+7.83%
|
-
|
|
May 09
2024
|
Erol R Akdamar Group President |
SELL
Bona fide gift
|
Direct |
5,139
-100.0%
|
-
|
|
May 09
2024
|
Jeffrey E. Cohen SVP-Government Relations |
SELL
Open market or private sale
|
Direct |
1,650
-24.14%
|
$516,450
$313.0 P/Share
|
|
May 09
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
6,311
-17.56%
|
$1,994,276
$316.88 P/Share
|
|
May 08
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Bona fide gift
|
Direct |
4,500
-11.13%
|
-
|
|
May 07
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,349
-23.4%
|
$3,877,586
$314.45 P/Share
|
|
May 07
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,660
+26.12%
|
$2,593,740
$139.06 P/Share
|
|
May 06
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
1,600
-4.48%
|
$494,400
$309.0 P/Share
|
|
May 03
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
890
-3.98%
|
$277,680
$312.0 P/Share
|
|
May 02
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
973
-4.17%
|
$303,576
$312.0 P/Share
|